Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT05870579
Ignite Creation Date: 2024-05-06 @ 7:03 PM
Last Modification Date: 2024-10-26 @ 2:59 PM
Study NCT ID: NCT05870579
Protocol Section: NCT05870579
Start Identification Module Data
Expand Identification Module Data
Brief Title: 177LuLu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER HER2- and GRPR Advanced Breast Cancer
Official Title: A Phase Ib Dose Finding Study Assessing Safety and Activity of 177LuLu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Advanced Breast Cancer Experiencing Early Relapse From NeoAdjuvant Endocrine Therapy or Who Have Progressed on Endocrine Therapy in Combination With a CDK46 Inhibitor for Advanced Disease
Acronym: None
Organization: Novartis
Organization Class: INDUSTRY
Organization Study ID: CAAA603B12101
Secondary IDs
Secondary ID Type Domain Link
2022-502465-18-00 OTHER EU CTIS None
Start Status Module Data
Status Verified Date: 2024-07
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Novartis Pharmaceuticals
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Novartis Pharmaceuticals
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload